baclofen + placebo botulinum toxin

This refers to a specific treatment arm in the **Baclotox** clinical trial (NCT00515398), a Phase 4 multicenter study sponsored by the **University Hospital, Toulouse** (CHU de Toulouse). This treatment regimen consists of active oral **baclofen** administered alongside a placebo intramuscular injection (placebo botulinum toxin) to maintain a double-blind, double-dummy design. Baclofen is a small molecule **GABA-B receptor agonist** used to treat muscle spasticity by inhibiting monosynaptic and polysynaptic reflexes at the spinal level. The trial specifically investigates whether early treatment of spasticity (within 2 months post-stroke) affects motor recovery, comparing the efficacy of oral baclofen against botulinum toxin type A injections. Merz Pharma provided financing and drug supplies for the study.

Other names

placebo + baclofenbaclofen arm of Baclotox trial